Base de dados : MEDLINE
Pesquisa : E02.642.249.245 [Categoria DeCS]
Referências encontradas : 1202 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 121 ir para página                         

  1 / 1202 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Registro de Ensaios Clínicos
Texto completo
[PMID]:29466592
[Au] Autor:Gardner CD; Trepanowski JF; Del Gobbo LC; Hauser ME; Rigdon J; Ioannidis JPA; Desai M; King AC
[Ad] Endereço:Stanford Prevention Research Center, Department of Medicine, Stanford University Medical School, Stanford, California.
[Ti] Título:Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion: The DIETFITS Randomized Clinical Trial.
[So] Source:JAMA;319(7):667-679, 2018 02 20.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: Dietary modification remains key to successful weight loss. Yet, no one dietary strategy is consistently superior to others for the general population. Previous research suggests genotype or insulin-glucose dynamics may modify the effects of diets. Objective: To determine the effect of a healthy low-fat (HLF) diet vs a healthy low-carbohydrate (HLC) diet on weight change and if genotype pattern or insulin secretion are related to the dietary effects on weight loss. Design, Setting, and Participants: The Diet Intervention Examining The Factors Interacting with Treatment Success (DIETFITS) randomized clinical trial included 609 adults aged 18 to 50 years without diabetes with a body mass index between 28 and 40. The trial enrollment was from January 29, 2013, through April 14, 2015; the date of final follow-up was May 16, 2016. Participants were randomized to the 12-month HLF or HLC diet. The study also tested whether 3 single-nucleotide polymorphism multilocus genotype responsiveness patterns or insulin secretion (INS-30; blood concentration of insulin 30 minutes after a glucose challenge) were associated with weight loss. Interventions: Health educators delivered the behavior modification intervention to HLF (n = 305) and HLC (n = 304) participants via 22 diet-specific small group sessions administered over 12 months. The sessions focused on ways to achieve the lowest fat or carbohydrate intake that could be maintained long-term and emphasized diet quality. Main Outcomes and Measures: Primary outcome was 12-month weight change and determination of whether there were significant interactions among diet type and genotype pattern, diet and insulin secretion, and diet and weight loss. Results: Among 609 participants randomized (mean age, 40 [SD, 7] years; 57% women; mean body mass index, 33 [SD, 3]; 244 [40%] had a low-fat genotype; 180 [30%] had a low-carbohydrate genotype; mean baseline INS-30, 93 µIU/mL), 481 (79%) completed the trial. In the HLF vs HLC diets, respectively, the mean 12-month macronutrient distributions were 48% vs 30% for carbohydrates, 29% vs 45% for fat, and 21% vs 23% for protein. Weight change at 12 months was -5.3 kg for the HLF diet vs -6.0 kg for the HLC diet (mean between-group difference, 0.7 kg [95% CI, -0.2 to 1.6 kg]). There was no significant diet-genotype pattern interaction (P = .20) or diet-insulin secretion (INS-30) interaction (P = .47) with 12-month weight loss. There were 18 adverse events or serious adverse events that were evenly distributed across the 2 diet groups. Conclusions and Relevance: In this 12-month weight loss diet study, there was no significant difference in weight change between a healthy low-fat diet vs a healthy low-carbohydrate diet, and neither genotype pattern nor baseline insulin secretion was associated with the dietary effects on weight loss. In the context of these 2 common weight loss diet approaches, neither of the 2 hypothesized predisposing factors was helpful in identifying which diet was better for whom. Trial Registration: clinicaltrials.gov Identifier: NCT01826591.
[Mh] Termos MeSH primário: Dieta com Restrição de Carboidratos
Dieta com Restrição de Gorduras
Dieta Redutora
Insulina/sangue
Obesidade/dietoterapia
[Mh] Termos MeSH secundário: Adulto
Ingestão de Energia
Feminino
Genótipo
Seres Humanos
Resistência à Insulina
Masculino
Meia-Idade
Obesidade/genética
Sobrepeso/dietoterapia
Sobrepeso/genética
Perda de Peso
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Insulin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2018.0245


  2 / 1202 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28747486
[Au] Autor:Chalvon-Demersay T; Even PC; Chaumontet C; Piedcoq J; Viollet B; Gaudichon C; Tomé D; Foretz M; Azzout-Marniche D
[Ad] Endereço:UMR Nutrition Physiology and Ingestive Behavior, AgroParisTech, INRA, Paris-Saclay University, Paris, France.
[Ti] Título:Modifying the Dietary Carbohydrate-to-Protein Ratio Alters the Postprandial Macronutrient Oxidation Pattern in Liver of AMPK-Deficient Mice.
[So] Source:J Nutr;147(9):1669-1676, 2017 09.
[Is] ISSN:1541-6100
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Hepatic AMP-activated kinase (AMPK) activity is sensitive to the dietary carbohydrate-to-protein ratio. However, the role of AMPK in metabolic adaptations to variations in dietary macronutrients remains poorly understood. The objective of this study was to determine the role of hepatic AMPK in the adaptation of energy metabolism in response to modulation of the dietary carbohydrate-to-protein ratio. Male 7-wk-old wild-type (WT) and liver AMPK-deficient (knockout) mice were fed either a normal-protein and normal-carbohydrate diet (NP-NC; 14% protein, 76% carbohydrate on an energy basis), a low-protein and high-carbohydrate diet (LP-HC; 5% protein, 85% carbohydrate), or a high-protein and low-carbohydrate diet (HP-LC; 55% protein, 35% carbohydrate) for 3 wk. During this period, after an overnight fast, metabolic parameters were measured and indirect calorimetry was performed in mice during the first hours after refeeding a 1-g calibrated meal of their own diet in order to investigate lipid and carbohydrate metabolism. Knockout mice fed an LP-HC or HP-LC meal exhibited 24% and 8% lower amplitudes in meal-induced carbohydrate and lipid oxidation changes. By contrast, knockout mice fed an NP-NC meal displayed normal carbohydrate and lipid oxidation profiles. These mice exhibited a transient increase in hepatic triglycerides and a decrease in hepatic glycogen. These changes were associated with a 650% higher secretion of fibroblast growth factor 21 (FGF21) 2 h after refeeding. The consequences of hepatic AMPK deletion depend on the dietary carbohydrate-to-protein ratio. In mice fed the NP-NC diet, deletion of AMPK in the liver led to an adaptation of liver metabolism resulting in increased secretion of FGF21. These changes possibly compensated for the absence of hepatic AMPK, as these mice exhibited normal postprandial changes in carbohydrate and lipid oxidation. By contrast, in mice fed the LP-HC and HP-LC diets, the lack of adjustment in liver metabolism in knockout mice resulted in a metabolic inflexibility, leading to a reduced amplitude of meal-induced changes in carbohydrate and lipid oxidation.
[Mh] Termos MeSH primário: Proteínas Quinases Ativadas por AMP/metabolismo
Metabolismo dos Carboidratos
Carboidratos da Dieta/administração & dosagem
Proteínas na Dieta/administração & dosagem
Metabolismo dos Lipídeos
Fígado/efeitos dos fármacos
Período Pós-Prandial
[Mh] Termos MeSH secundário: Proteínas Quinases Ativadas por AMP/deficiência
Adaptação Fisiológica
Animais
Dieta
Dieta com Restrição de Carboidratos
Dieta com Restrição de Proteínas
Carboidratos da Dieta/metabolismo
Carboidratos da Dieta/farmacologia
Gorduras na Dieta/metabolismo
Proteínas na Dieta/metabolismo
Proteínas na Dieta/farmacologia
Metabolismo Energético/efeitos dos fármacos
Jejum
Fatores de Crescimento de Fibroblastos/metabolismo
Glicogênio/metabolismo
Fígado/metabolismo
Masculino
Refeições
Camundongos Knockout
Oxirredução
Triglicerídeos/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Dietary Carbohydrates); 0 (Dietary Fats); 0 (Dietary Proteins); 0 (Triglycerides); 0 (fibroblast growth factor 22, mouse); 62031-54-3 (Fibroblast Growth Factors); 9005-79-2 (Glycogen); EC 2.7.11.31 (AMP-Activated Protein Kinases)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171215
[Lr] Data última revisão:
171215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170728
[St] Status:MEDLINE
[do] DOI:10.3945/jn.117.250803


  3 / 1202 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28958691
[Au] Autor:Haufe S; Engeli S; Kaminski J; Witt H; Rein D; Kamlage B; Utz W; Fuhrmann JC; Haas V; Mähler A; Schulz-Menger J; Luft FC; Boschmann M; Jordan J
[Ad] Endereço:Institute for Clinical Pharmacology, Hannover Medical School, Hannover, Germany.
[Ti] Título:Branched-chain amino acid catabolism rather than amino acids plasma concentrations is associated with diet-induced changes in insulin resistance in overweight to obese individuals.
[So] Source:Nutr Metab Cardiovasc Dis;27(10):858-864, 2017 Oct.
[Is] ISSN:1590-3729
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND & AIMS: 3-Hydroxyisobutyrate (3-HIB), a catabolic intermediate of the BCAA valine, which stimulates muscle fatty acid uptake, has been implicated in the pathogenesis of insulin resistance. We tested the hypothesis that circulating 3-HIB herald insulin resistance and that metabolic improvement with weight loss are related to changes in BCAAs and 3-HIB. METHODS AND RESULTS: We analyzed plasma and urine in 109 overweight to obese individuals before and after six months on hypocaloric diets reduced in either carbohydrates or fat. We calculated the homeostasis model assessment index (HOMA-IR) and whole body insulin sensitivity from oral glucose tolerance tests and measured intramyocellular fat by magnetic resonance spectroscopy. BCAAs and 3-HIB plasma concentrations were inversely related to insulin sensitivity but not to intramyocellular fat content at baseline. With 7.4 ± 4.5% weight loss mean BCAA and 3-HIB plasma concentrations did not change, irrespective of dietary macronutrient content. Individual changes in 3-HIB with 6-month diet but not BCAAs were correlated to the change in whole body insulin sensitivity and HOMA-IR independently of BMI changes. CONCLUSIONS: 3-HIB relates to insulin sensitivity but is not associated with intramyocellular fat content in overweight to obese individuals. Moreover, changes in 3-HIB rather than changes in BCAAs are associated with metabolic improvements with weight loss. Registration number for clinical trials: ClinicalTrials.gov Identifier: NCT00956566.
[Mh] Termos MeSH primário: Aminoácidos de Cadeia Ramificada/sangue
Restrição Calórica
Dieta com Restrição de Carboidratos
Dieta com Restrição de Gorduras
Hidroxibutiratos/sangue
Resistência à Insulina
Obesidade/dietoterapia
Perda de Peso
[Mh] Termos MeSH secundário: Tecido Adiposo/metabolismo
Adulto
Biomarcadores/sangue
Glicemia/metabolismo
Feminino
Teste de Tolerância a Glucose
Seres Humanos
Insulina/sangue
Espectroscopia de Ressonância Magnética
Masculino
Metabolômica/métodos
Meia-Idade
Músculo Esquelético/metabolismo
Obesidade/sangue
Obesidade/diagnóstico
Estudos Prospectivos
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Amino Acids, Branched-Chain); 0 (Biomarkers); 0 (Blood Glucose); 0 (Hydroxybutyrates); 0 (Insulin); K75C8JDF5W (3-hydroxyisobutyric acid)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170930
[St] Status:MEDLINE


  4 / 1202 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28903954
[Au] Autor:Beaumont M; Portune KJ; Steuer N; Lan A; Cerrudo V; Audebert M; Dumont F; Mancano G; Khodorova N; Andriamihaja M; Airinei G; Tomé D; Benamouzig R; Davila AM; Claus SP; Sanz Y; Blachier F
[Ad] Endereço:Mixed research unit Nutrition Physiology and Ingestive Behavior, AgroParisTech, French National Institute for Agricultural Research (INRA), University of Paris-Saclay, Paris, France.
[Ti] Título:Quantity and source of dietary protein influence metabolite production by gut microbiota and rectal mucosa gene expression: a randomized, parallel, double-blind trial in overweight humans.
[So] Source:Am J Clin Nutr;106(4):1005-1019, 2017 Oct.
[Is] ISSN:1938-3207
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Although high-protein diets (HPDs) are frequently consumed for body-weight control, little is known about the consequences for gut microbiota composition and metabolic activity and for large intestine mucosal homeostasis. Moreover, the effects of HPDs according to the source of protein need to be considered in this context. The objective of this study was to evaluate the effects of the quantity and source of dietary protein on microbiota composition, bacterial metabolite production, and consequences for the large intestinal mucosa in humans. A randomized, double-blind, parallel-design trial was conducted in 38 overweight individuals who received a 3-wk isocaloric supplementation with casein, soy protein, or maltodextrin as a control. Fecal and rectal biopsy-associated microbiota composition was analyzed by 16S ribosomal DNA sequencing. Fecal, urinary, and plasma metabolomes were assessed by H-nuclear magnetic resonance. Mucosal transcriptome in rectal biopsies was determined with the use of microarrays. HPDs did not alter the microbiota composition, but induced a shift in bacterial metabolism toward amino acid degradation with different metabolite profiles according to the protein source. Correlation analysis identified new potential bacterial taxa involved in amino acid degradation. Fecal water cytotoxicity was not modified by HPDs, but was associated with a specific microbiota and bacterial metabolite profile. Casein and soy protein HPDs did not induce inflammation, but differentially modified the expression of genes playing key roles in homeostatic processes in rectal mucosa, such as cell cycle or cell death. This human intervention study shows that the quantity and source of dietary proteins act as regulators of gut microbiota metabolite production and host gene expression in the rectal mucosa, raising new questions on the impact of HPDs on the large intestine mucosa homeostasis. This trial was registered at clinicaltrials.gov as NCT02351297.
[Mh] Termos MeSH primário: Bactérias/metabolismo
Dieta com Restrição de Carboidratos
Proteínas na Dieta/farmacologia
Microbioma Gastrointestinal
Mucosa Intestinal/metabolismo
Intestino Grosso/metabolismo
Transcriptoma
[Mh] Termos MeSH secundário: Adulto
Aminoácidos/metabolismo
Bactérias/genética
Caseínas/farmacologia
DNA Bacteriano/análise
Proteínas na Dieta/administração & dosagem
Proteínas na Dieta/metabolismo
Método Duplo-Cego
Fezes
Feminino
Homeostase
Seres Humanos
Mucosa Intestinal/microbiologia
Intestino Grosso/microbiologia
Masculino
Obesidade/dietoterapia
RNA Ribossômico 16S
Reto/metabolismo
Reto/microbiologia
Proteínas de Soja/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Amino Acids); 0 (Caseins); 0 (DNA, Bacterial); 0 (Dietary Proteins); 0 (RNA, Ribosomal, 16S); 0 (Soybean Proteins)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170915
[St] Status:MEDLINE
[do] DOI:10.3945/ajcn.117.158816


  5 / 1202 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28855223
[Au] Autor:Derkach A; Sampson J; Joseph J; Playdon MC; Stolzenberg-Solomon RZ
[Ad] Endereço:Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, MD; and.
[Ti] Título:Effects of dietary sodium on metabolites: the Dietary Approaches to Stop Hypertension (DASH)-Sodium Feeding Study.
[So] Source:Am J Clin Nutr;106(4):1131-1141, 2017 Oct.
[Is] ISSN:1938-3207
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:High sodium intake is known to increase blood pressure and is difficult to measure in epidemiologic studies. We examined the effect of sodium intake on metabolites within the DASH (Dietary Approaches to Stop Hypertension Trial)-Sodium Trial to further our understanding of the biological effects of sodium intake beyond blood pressure. The DASH-Sodium Trial randomly assigned individuals to either the DASH diet (low in fat and high in protein, low-fat dairy, and fruits and vegetables) or a control diet for 12 wk. Participants within each diet arm received, in random order, diets containing high (150 nmol or 3450 mg), medium (100 nmol or 2300 mg), and low (50 nmol or 1150 mg) amounts of sodium for 30 d (crossover design). Fasting blood samples were collected at the end of each sodium intervention. We measured 531 identified plasma metabolites in 73 participants at the end of their high- and low-sodium interventions and in 46 participants at the end of their high- and medium-sodium interventions ( = 119). We used linear mixed-effects regression to model the relation between each log-transformed metabolite and sodium intake. We also combined the resulting values with Fisher's method to estimate the association between sodium intake and 38 metabolic pathways or groups. Six pathways were associated with sodium intake at a Bonferroni-corrected threshold of 0.0013 (e.g., fatty acid, food component or plant, benzoate, γ-glutamyl amino acid, methionine, and tryptophan). Although 82 metabolites were associated with sodium intake at a false discovery rate ≤0.10, only 4-ethylphenylsufate, a xenobiotic related to benzoate metabolism, was significant at a Bonferroni-corrected threshold ( < 10 ). Adjustment for coinciding change in blood pressure did not substantively alter the association for the top-ranked metabolites. Sodium intake is associated with changes in circulating metabolites, including gut microbial, tryptophan, plant component, and γ-glutamyl amino acid-related metabolites. This trial was registered at clinicaltrials.gov as NCT00000608.
[Mh] Termos MeSH primário: Dieta
Comportamento Alimentar
Hipertensão/sangue
Metaboloma/efeitos dos fármacos
Cloreto de Sódio na Dieta/farmacologia
Sódio na Dieta/farmacologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Aminoácidos/sangue
Pressão Sanguínea
Estudos Cross-Over
Dieta com Restrição de Carboidratos
Dieta com Restrição de Gorduras
Dieta Hipossódica
Feminino
Frutas
Microbioma Gastrointestinal
Seres Humanos
Hipertensão/dietoterapia
Masculino
Redes e Vias Metabólicas/efeitos dos fármacos
Meia-Idade
Extratos Vegetais/sangue
Cloreto de Sódio na Dieta/administração & dosagem
Sódio na Dieta/administração & dosagem
Verduras
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Amino Acids); 0 (Plant Extracts); 0 (Sodium Chloride, Dietary); 0 (Sodium, Dietary)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170901
[St] Status:MEDLINE
[do] DOI:10.3945/ajcn.116.150136


  6 / 1202 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28814394
[Au] Autor:Tsaban G; Wolak A; Avni-Hassid H; Gepner Y; Shelef I; Henkin Y; Schwarzfuchs D; Cohen N; Bril N; Rein M; Serfaty D; Kenigsbuch S; Tene L; Zelicha H; Yaskolka-Meir A; Komy O; Bilitzky A; Chassidim Y; Ceglarek U; Stumvoll M; Blüher M; Thiery J; Dicker D; Rudich A; Stampfer MJ; Shai I
[Ad] Endereço:Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
[Ti] Título:Dynamics of intrapericardial and extrapericardial fat tissues during long-term, dietary-induced, moderate weight loss.
[So] Source:Am J Clin Nutr;106(4):984-995, 2017 Oct.
[Is] ISSN:1938-3207
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In view of evidence linking pericardial fat accumulation with increased cardiovascular disease risk, strategies to reduce its burden are needed. Data comparing the effects of specific long-term dietary interventions on pericardial fat tissue mobilization are sparse. We sought to evaluate intrapericardial-fat (IPF) and extrapericardial-fat (EPF) changes during weight-loss interventions by different dietary regimens. During 18 mo of a randomized controlled trial, we compared a Mediterranean/low-carbohydrate (MED/LC) diet plus 28 g walnuts/d with a calorically equal low-fat (LF) diet among randomly assigned participants with moderate abdominal obesity. We performed whole-body MRI and volumetrically quantified IPF and EPF among 80 participants to follow the 18-mo changes. The participants [mean age: 48.6 y; mean body mass index (BMI; in kg/m ); 31.7; 90% men] had baseline IPF and EPF (mean ± SD) volumes of 172.4 ± 53.3 mL and 194.9 ± 71.5 mL, respectively. The 18-mo moderate weight loss of 3.7 kg was similar in both groups, but the reduction in waist circumference was higher in the MED/LC group (-6.9 ± 6.6 cm) than in the LF diet group (-2.3 ± 6.5 cm; = 0.01). After 18 mo, the IPF volume had reduced twice as much in the MED/LC group compared with the LF group [-37 ± 26.2 mL (-22% ± 15%) compared with -15.5 ± 26.2 mL (-8% ± 15%), respectively; < 0.05, after adjustment for changes in weight or visceral adipose tissue]. The EPF volume had reduced similarly in both groups [-41.6 ± 30.2 mL (-23% ± 16%) in the MED/LC group compared with -37.9 ± 28.3 mL (-19% ± 14%) in the LF group; > 0.1]. After controlling for weight loss, IPF and EPF volume reduction paralleled changes in lipid profile but not with improved glycemic profile variables: the IPF relative reduction was associated with a decrease in triglycerides (TGs) (ß = 0.090; 95% CI: 0.026, 0.154; = 0.007) and the ratio of TGs to high-density lipoprotein (HDL) cholesterol (ß = 2.689; 95% CI: 0.373, 5.003; = 0.024), and the EPF relative reduction was associated with an increase in HDL cholesterol (ß = -0.452; 95% CI: -0.880, -0.023; = 0.039) and a decrease in total cholesterol and HDL cholesterol (ß = 3.766; 95% CI: 1.092, 6.440; = 0.007). Moderate but persistent dietary-induced weight loss substantially decreased both IPF and EPF volumes. Reduction of pericardial adipose tissues is independently associated with an improved lipid profile. The Mediterranean diet, rich in unsaturated fats and restricted carbohydrates, is superior to an LF diet in terms of the IPF burden reduction. This trial was registered at clinicaltrials.gov as NCT01530724.
[Mh] Termos MeSH primário: Tecido Adiposo/metabolismo
Dieta Redutora/métodos
Carboidratos da Dieta/farmacologia
Gorduras na Dieta/farmacologia
Obesidade/dietoterapia
Pericárdio/metabolismo
Perda de Peso/fisiologia
[Mh] Termos MeSH secundário: Adiposidade
Adulto
Índice de Massa Corporal
Dieta com Restrição de Carboidratos
Dieta com Restrição de Gorduras
Dieta Mediterrânea
Carboidratos da Dieta/administração & dosagem
Gorduras na Dieta/administração & dosagem
Gorduras na Dieta/metabolismo
Feminino
Seres Humanos
Gordura Intra-Abdominal
Lipídeos/sangue
Masculino
Meia-Idade
Nozes
Obesidade/sangue
Obesidade Abdominal/sangue
Obesidade Abdominal/dietoterapia
Circunferência da Cintura
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dietary Carbohydrates); 0 (Dietary Fats); 0 (Lipids)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170818
[St] Status:MEDLINE
[do] DOI:10.3945/ajcn.117.157115


  7 / 1202 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28754198
[Au] Autor:Roehl K; Sewak SL
[Ti] Título:Practice Paper of the Academy of Nutrition and Dietetics: Classic and Modified Ketogenic Diets for Treatment of Epilepsy.
[So] Source:J Acad Nutr Diet;117(8):1279-1292, 2017 Aug.
[Is] ISSN:2212-2672
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Ketogenic diet (KD) therapy is an established form of treatment for both pediatric and adult patients with intractable epilepsy. Ketogenic diet is a term that refers to any diet therapy in which dietary composition would be expected to result in a ketogenic state of human metabolism. While historically considered a last-resort therapy, classic KDs and their modified counterparts, including the modified Atkins diet and low glycemic index treatment, are gaining ground for use across the spectrum of seizure disorders. Registered dietitian nutritionists are often the first line and the most influential team members when it comes to treating those on KD therapy. This paper offers registered dietitian nutritionists insight into the history of KD therapy, an overview of the various diets, and a brief review of the literature with regard to efficacy; provides basic guidelines for practical implementation and coordination of care across multiple health care and community settings; and describes the role of registered dietitian nutritionists in achieving successful KD therapy.
[Mh] Termos MeSH primário: Academias e Institutos
Dieta Cetogênica
Dietética
Epilepsia/dietoterapia
[Mh] Termos MeSH secundário: Pré-Escolar
Dieta com Restrição de Carboidratos
Carboidratos da Dieta/administração & dosagem
Gorduras na Dieta/administração & dosagem
Proteínas na Dieta/administração & dosagem
Metabolismo Energético
Índice Glicêmico
Seres Humanos
Lactente
Avaliação Nutricional
Nutricionistas
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dietary Carbohydrates); 0 (Dietary Fats); 0 (Dietary Proteins)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170730
[St] Status:MEDLINE


  8 / 1202 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28701319
[Au] Autor:Winwood-Smith HS; Franklin CE; White CR
[Ad] Endereço:School of Biological Sciences, University of Queensland, Brisbane, Queensland, Australia; and h.winwoodsmith@uq.edu.au.
[Ti] Título:Low-carbohydrate diet induces metabolic depression: a possible mechanism to conserve glycogen.
[So] Source:Am J Physiol Regul Integr Comp Physiol;313(4):R347-R356, 2017 Oct 01.
[Is] ISSN:1522-1490
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Long-term studies have found that low-carbohydrate diets are more effective for weight loss than calorie-restricted diets in the short term but equally or only marginally more effective in the long term. Low-carbohydrate diets have been linked to reduced glycogen stores and increased feelings of fatigue. We propose that reduced physical activity in response to lowered glycogen explains the diminishing weight loss advantage of low-carbohydrate compared with low-calorie diets over longer time periods. We explored this possibility by feeding adult a standard or a low-carbohydrate diet for 9 days and measured changes in metabolic rate, glycogen stores, activity, and body mass. We hypothesized that a low-carbohydrate diet would cause a reduction in glycogen stores, which recover over time, a reduction in physical activity, and an increase in resting metabolic rate. The low-carbohydrate diet reduced glycogen stores, which recovered over time. Activity was unaffected by diet, but metabolic rate was reduced, in the low-carbohydrate group. We conclude that metabolic depression could explain the decreased effectiveness of low-carbohydrate diets over time and recommend further investigation of long-term metabolic effects of dietary interventions and a greater focus on physiological plasticity within the study of human nutrition.
[Mh] Termos MeSH primário: Dieta com Restrição de Carboidratos/métodos
Carboidratos da Dieta/metabolismo
Drosophila melanogaster/fisiologia
Metabolismo Energético/fisiologia
Glicogênio/metabolismo
Esforço Físico/fisiologia
[Mh] Termos MeSH secundário: Animais
Carboidratos da Dieta/administração & dosagem
Metabolismo Energético/efeitos dos fármacos
Feminino
Masculino
Esforço Físico/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dietary Carbohydrates); 9005-79-2 (Glycogen)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171006
[Lr] Data última revisão:
171006
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170714
[St] Status:MEDLINE
[do] DOI:10.1152/ajpregu.00067.2017


  9 / 1202 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28625832
[Au] Autor:Staudacher HM; Lomer MCE; Farquharson FM; Louis P; Fava F; Franciosi E; Scholz M; Tuohy KM; Lindsay JO; Irving PM; Whelan K
[Ad] Endereço:Faculty of Life Sciences and Medicine, Diabetes and Nutritional Sciences Division, King's College London, London, United Kingdom.
[Ti] Título:A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial.
[So] Source:Gastroenterology;153(4):936-947, 2017 Oct.
[Is] ISSN:1528-0012
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND & AIMS: Dietary restriction of fermentable carbohydrates (a low FODMAP diet) has been reported to reduce symptoms in some patients with irritable bowel syndrome (IBS). We performed a randomized, placebo-controlled study to determine its effects on symptoms and the fecal microbiota in patients with IBS. METHODS: We performed a 2×2 factorial trial of 104 patients with IBS (18-65 years old), based on the Rome III criteria, at 2 hospitals in the United Kingdom. Patients were randomly assigned (blinded) to groups given counselling to follow a sham diet or diet low in FODMAPs for 4 weeks, along with a placebo or multistrain probiotic formulation, resulting in 4 groups (27 receiving sham diet/placebo, 26 receiving sham diet/probiotic, 24 receiving low FODMAP diet /placebo, and 27 receiving low FODMAP diet/probiotic). The sham diet restricted a similar number of staple and non-staple foods as the low FODMAP diet; the diets had similar degrees of difficulty to follow. Dietary counselling was given to patients in all groups and data on foods eaten and compliance were collected. The incidence and severity of 15 gastrointestinal symptoms and overall symptoms were measured daily for 7 days before the study period; along with stool frequency and consistency. At baseline, global and individual symptoms were measured, along with generic and disease-specific health-related quality of life, using standard scoring systems. All data were collected again at 4 weeks, and patients answered questions about adequate symptom relief. Fecal samples were collected at baseline and after 4 weeks and analyzed by quantitative PCR and 16S rRNA sequencing. The co-primary endpoints were adequate relief of symptoms and stool Bifidobacterium species abundance at 4 weeks. RESULTS: There was no significant interaction between the interventions in adequate relief of symptoms (P = .52) or Bifidobacterium species (P = .68). In the intention-to-treat analysis, a higher proportion of patients in the low FODMAP diet had adequate symptom relief (57%) than in the sham diet group (38%), although the difference was not statistically significant (P = .051). In the per-protocol analysis, a significantly higher proportion of patients on the low FODMAP diet had adequate symptom relief (61%) than in the sham diet group (39%) (P = .042). Total mean IBS-Severity Scoring System score was significantly lower for patients on the low FODMAP diet (173 ± 95) than the sham diet (224 ± 89) (P = .001), but not different between those given probiotic (207 ± 98) or placebo (192 ± 93) (P = .721) Abundance of Bifidobacterium species was lower in fecal samples from patients on the low FODMAP diet (8.8 rRNA genes/g) than patients on the sham diet (9.2 rRNA genes/g) (P = .008), but higher in patients given probiotic (9.1 rRNA genes/g) than patients given placebo (8.8 rRNA genes/g) (P = .019). There was no effect of the low FODMAP diet on microbiota diversity in fecal samples. CONCLUSIONS: In a placebo-controlled study of patients with IBS, a low FODMAP diet associates with adequate symptom relief and significantly reduced symptom scores compared with placebo. It is not clear whether changes resulted from collective FODMAP restriction or removal of a single component, such as lactose. Co-administration of the multistrain probiotic increased numbers of Bifidobacterium species, compared with placebo, and might be given to restore these bacteria to patients on a low FODMAP diet. Trial registration no: ISRCTN02275221.
[Mh] Termos MeSH primário: Bifidobacterium/crescimento & desenvolvimento
Dieta com Restrição de Carboidratos
Carboidratos da Dieta/efeitos adversos
Microbioma Gastrointestinal
Intestinos/microbiologia
Síndrome do Intestino Irritável/dietoterapia
Probióticos/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Bifidobacterium/classificação
Bifidobacterium/genética
Terapia Combinada
Carboidratos da Dieta/metabolismo
Fezes/microbiologia
Feminino
Fermentação
Seres Humanos
Síndrome do Intestino Irritável/diagnóstico
Síndrome do Intestino Irritável/microbiologia
Londres
Masculino
Meia-Idade
Qualidade de Vida
Indução de Remissão
Ribotipagem
Índice de Gravidade de Doença
Inquéritos e Questionários
Fatores de Tempo
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Dietary Carbohydrates)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170620
[St] Status:MEDLINE


  10 / 1202 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28440580
[Au] Autor:Krogsgaard LR; Lyngesen M; Bytzer P
[Ad] Endereço:Department of Gastroenterology, Zealand University Hospital, Køge, Denmark.
[Ti] Título:Systematic review: quality of trials on the symptomatic effects of the low FODMAP diet for irritable bowel syndrome.
[So] Source:Aliment Pharmacol Ther;45(12):1506-1513, 2017 Jun.
[Is] ISSN:1365-2036
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The low Fermentable Oligo-, Di- Monosaccharides, and Polyoles (FODMAP) diet is a new treatment option for irritable bowel syndrome (IBS). Experts refer to the diet as supported by high level of evidence, but an evaluation of the quality of trials is lacking. AIM: To provide a systematic review of the quality of trials on the symptomatic effects of the low FODMAP diet for IBS. METHODS: Pubmed and EMBASE were searched for randomised controlled trials (RCTs) reporting effect of the low FODMAP diet on IBS symptoms. The quality of trials was evaluated by estimating risk of bias and assessing trial methodology. RESULTS: Nine RCTs were eligible, including 542 patients. The intervention period was from 2 days to 6 weeks and one trial included a 6-month follow-up. Three trials intervened by providing meals, controlling with a diet high in FODMAP content. In six trials, the intervention was instruction by a dietician and a variety of control interventions were used, all with limited established efficacy. Domains with a high risk of bias were identified for all the trials. High risk of bias dominated domains regarding blinding, with only one trial double-blinded. CONCLUSIONS: The RCTs on the low FODMAP diet are characterized by high risk of bias. The diet has not been studied in a randomised, controlled setting for more than 6 weeks and trials examining the effect of the important reintroduction period are lacking. There is a risk that the symptomatic effects reported in the trials are driven primarily by a placebo response.
[Mh] Termos MeSH primário: Dieta com Restrição de Carboidratos
Dissacarídeos/administração & dosagem
Síndrome do Intestino Irritável/dietoterapia
Monossacarídeos/administração & dosagem
Oligossacarídeos/administração & dosagem
Polímeros/administração & dosagem
[Mh] Termos MeSH secundário: Carboidratos da Dieta/administração & dosagem
Comportamento Alimentar
Fermentação
Seres Humanos
Síndrome do Intestino Irritável/epidemiologia
Qualidade da Assistência à Saúde
Ensaios Clínicos Controlados Aleatórios como Assunto/normas
Ensaios Clínicos Controlados Aleatórios como Assunto/estatística & dados numéricos
Projetos de Pesquisa
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Dietary Carbohydrates); 0 (Disaccharides); 0 (Monosaccharides); 0 (Oligosaccharides); 0 (Polymers); 0 (polyol)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171006
[Lr] Data última revisão:
171006
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170426
[St] Status:MEDLINE
[do] DOI:10.1111/apt.14065



página 1 de 121 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde